Agios Pharmaceuticals reported a substantial revenue beat for the third quarter of 2026, primarily driven by the accelerated U.S. commercial adoption of AQVESME (mitapivat) following its January launch. While the company narrowed its net loss compared to the prior year, it faced a three-month extension for its sickle cell disease sNDA review, now targeting February 2027.
Key Highlights
- Worldwide mitapivat net revenue reached $55.4 million, representing more than a 4x increase over the $12.9 million reported in the third quarter of 2025.
- U.S. commercial demand for AQVESME in thalassemia yielded 619 cumulative start forms by quarter-end, with sequential U.S. revenue growth of 20%.
- The FDA extended the PDUFA goal date for the sickle cell disease application to February 1, 2027, to evaluate REMS requirements, though the company remains launch-ready.
- Cash and marketable securities stood at $907.0 million, supported by a planned 35% reduction in R&D headcount to reach non-GAAP profitability by 2028.